GSK plc (LON:GSK) Receives Consensus Recommendation of "Moderate Buy" from Analysts

GSK plc (LON:GSK - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven brokerages that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is GBX 1,805.83 ($22.49).

A number of analysts have commented on GSK shares. JPMorgan Chase & Co. reaffirmed an "underweight" rating on shares of GSK in a report on Tuesday, January 7th. Berenberg Bank decreased their price objective on GSK from GBX 1,820 ($22.66) to GBX 1,600 ($19.92) and set a "buy" rating for the company in a research note on Friday, November 29th.

GSK Price Performance

Shares of GSK stock traded down GBX 12.41 ($0.15) during trading hours on Friday, reaching GBX 1,453.09 ($18.09). 5,846,945 shares of the company were exchanged, compared to its average volume of 28,223,463. GSK has a fifty-two week low of GBX 1,282.50 ($15.97) and a fifty-two week high of GBX 1,823.50 ($22.71). The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73. The stock's fifty day moving average is GBX 1,361.34 and its two-hundred day moving average is GBX 1,455.93. The company has a market cap of £59.29 billion, a price-to-earnings ratio of 1,285.92, a P/E/G ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) earnings per share (EPS) for the quarter. GSK had a net margin of 12.83% and a return on equity of 33.30%. Sell-side analysts forecast that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Jonathan Symonds bought 1,500 shares of the company's stock in a transaction on Friday, December 20th. The shares were purchased at an average cost of GBX 1,315 ($16.37) per share, for a total transaction of £19,725 ($24,561.08). 1.61% of the stock is currently owned by company insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.